Armelle Vinceneux
Centre Léon Bérard(FR)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Pancreatic and Hepatic Oncology Research, Renal cell carcinoma treatment, Cancer Genomics and Diagnostics, Prostate Cancer Treatment and Research
Most-Cited Works
- → Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis(2016)118 cited
- → Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF)(2017)52 cited
- → 5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study(2018)38 cited
- → Ductal adenocarcinoma of the prostate: Clinical and biological profiles(2017)33 cited
- → Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRPα inhibitor: Results of monotherapy dose escalation in phase 1 study in patients with advanced solid tumors.(2021)26 cited
- → A multicentric, single arm, open-label, phase I/II study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer (PRadR)(2024)16 cited
- → Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study(2025)15 cited
- → Patients’ selection and trial matching in early-phase oncology clinical trials(2024)12 cited
- → 983P Phase I dose escalation study in patients (pts) with advanced solid tumours receiving first-in-class BI 765063, a selective signal-regulatory protein α (SIRPα) inhibitor, in combination with ezabenlimab (BI 754091), a programmed cell death protein 1 (PD-1) inhibitor(2021)11 cited
- → Abstract CT119: A first-in-human phase 1 study of LOXO-435, a potent, highly isoform-selective FGFR3 inhibitor in advanced solid tumors with FGFR3 alterations (trial in progress)(2023)9 cited